Trials / Completed
CompletedNCT02388594
A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients
A Phase I Study of T-Cells Genetically Modified at the CCR5 Gene by Zinc Finger Nucleases SB-728mR in HIV-Infected Patients, With or Without the CCR5 Delta-32 Mutation, Pre-treated With Cyclophosphamide
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 14 (actual)
- Sponsor
- University of Pennsylvania · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a triple cohort, open-label pilot study of the safety and antiviral activity of a single infusion of autologous CD4+ T cells genetically modified at the CCR5 gene by Zinc Finger Nucleases SB-728mR (ZFN Modified CD4+ T Cells) using electroporated mRNA with or without the prior administration of two different doses of cyclophosphamide.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZFN Modified CD4+ T Cells | |
| DRUG | Cyclophosphamide |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2018-09-01
- Completion
- 2019-03-01
- First posted
- 2015-03-17
- Last updated
- 2019-04-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02388594. Inclusion in this directory is not an endorsement.